glp-1 agonist weight gain effects November Blog GLP-1 Agonists For Obesity In

10.1152/ajpendo.00236.2023

Now nothing works. We hear it every day

Rare cases of pulmonary hypertension have been reported with phentermine alone, though the absolute risk appears low

Key Points Question Is the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in patients with type 2 diabetes (T2D) associated with an increased risk of sight-threatening diabetic retinopathy (DR) or nonarteritic anterior ischemic optic neuropathy (NAION)

For individuals managing weight or metabolic health while breastfeeding, this decision requires balancing treatment goals with infant safety

Whether these factors provide meaningful advantages depends on individual priorities